Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics

Nerea Martín Almazán, Afsar Rahbar, Marcus Carlsson, Tove Hoffman, Linda Kolstad, Bengt Rönnberg, Mattia Russel Pantalone, Ilona Lewensohn Fuchs, Anna Nauclér, Mats Ohlin, Mariusz Sacharczuk, Piotr Religa, Stefan Amér, Christian Molnár, Åke Lundkvist, Andres Susrud, Birger Sörensen, Cecilia Söderberg-Nauclér
doi: https://doi.org/10.1101/2021.12.23.21268321
Nerea Martín Almazán
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
3Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Afsar Rahbar
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cecilia.naucler{at}ki.se afsar.rahbar{at}ki.se
Marcus Carlsson
4Centre for the Mathematical Sciences, Lund University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tove Hoffman
5Zoonosis Science Center (ZSC), Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Kolstad
5Zoonosis Science Center (ZSC), Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt Rönnberg
5Zoonosis Science Center (ZSC), Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mattia Russel Pantalone
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilona Lewensohn Fuchs
6Division of Clinical Microbiology, Department of Labortory Medicine, Karolinska Institutet, Stockholm, Sweden
7Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Nauclér
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mats Ohlin
8Department of Immunotechnology and SciLifeLab Human Antibody Therapeutics Infrastructure Unit, Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariusz Sacharczuk
9Faculty of Pharmacy with the Laboratory Medicine Division, Department of Pharmacodynamics, Medical University of Warsaw, Centre for Preclinical Research and Technology, Banacha 1B, Warsaw, Poland
10Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, Jastrzebiec, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piotr Religa
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
10Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, Jastrzebiec, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Amér
11Familjeläkarna Saltsjöbaden, Saltsjöbaden, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Molnár
11Familjeläkarna Saltsjöbaden, Saltsjöbaden, Sweden
12Department of Neurobiology, Care Sciences and Society, NVS, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Åke Lundkvist
5Zoonosis Science Center (ZSC), Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andres Susrud
13Immunor AS, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birger Sörensen
13Immunor AS, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecilia Söderberg-Nauclér
1Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cecilia.naucler{at}ki.se afsar.rahbar{at}ki.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Susceptibility to SARS-CoV-2 infections is highly variable, ranging from asymptomatic and mild infections in most, to deadly outcome in few. Here, we present evidence that antibodies induced by currently circulating influenza A H1N1 (flu) strains cross react with the most critical receptor binding motif of the SARS-CoV-2 spike protein that interacts with the ACE2 receptor. About 58– 68% of blood donors in Stockholm had detectable antibodies to this cross-reactive peptide, NGVEGF, and seasonal flu vaccination trended to enhance binding of inhibitory antibodies to SARS-CoV-2. This peptide also activated CD8 T cells in 20% of healthy subjects. Eleven additional CD8 T-cell peptides that cross-react with flu and SARS-CoV-2 were identified that potentially protect against SARS-CoV-2 in 40–71% of individuals, depending on their HLA type.

One-Sentence Summary Flu-mediated pre-immunity to SARS-CoV-2 may protect against COVID-19 and likely affects herd immunity thresholds.

Competing Interest Statement

BS and AS have submitted a patent application concerning a peptide Covid19 vaccine.

Funding Statement

This research was partially funded by the Swedish Research Council (VR: 2019-01736. 2017-05807. 2018-02569). The European Unions Horizon 2020 Research Innovation Program under grant 874735 (VEO). The Knut and Alice Wallenberg Foundation and the Science for Life Laboratory Uppsala (Projects: Nevermore Covid SiCoV and Molres).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethics Committee at Karolinska Institutet, Stockholm, Sweden (Dnr 2020-06333: all vaccinated subjects gave written informed consent; blood donors from blood bank were anonymous; Dnr 2020-07232: all subjects gave written informed consent; Dnr 06400: included anonymous blood samples from healthy donors (HD) in 2011 (Dnr: 01-420) and in 1996 (Dnr: 95-397 and 02-091). Ethical approval was obtained for the animal study (Dnr 16.07.2021).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics
Nerea Martín Almazán, Afsar Rahbar, Marcus Carlsson, Tove Hoffman, Linda Kolstad, Bengt Rönnberg, Mattia Russel Pantalone, Ilona Lewensohn Fuchs, Anna Nauclér, Mats Ohlin, Mariusz Sacharczuk, Piotr Religa, Stefan Amér, Christian Molnár, Åke Lundkvist, Andres Susrud, Birger Sörensen, Cecilia Söderberg-Nauclér
medRxiv 2021.12.23.21268321; doi: https://doi.org/10.1101/2021.12.23.21268321
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics
Nerea Martín Almazán, Afsar Rahbar, Marcus Carlsson, Tove Hoffman, Linda Kolstad, Bengt Rönnberg, Mattia Russel Pantalone, Ilona Lewensohn Fuchs, Anna Nauclér, Mats Ohlin, Mariusz Sacharczuk, Piotr Religa, Stefan Amér, Christian Molnár, Åke Lundkvist, Andres Susrud, Birger Sörensen, Cecilia Söderberg-Nauclér
medRxiv 2021.12.23.21268321; doi: https://doi.org/10.1101/2021.12.23.21268321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13381)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5155)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3271)
  • Health Policy (1142)
  • Health Systems and Quality Improvement (1191)
  • Hematology (431)
  • HIV/AIDS (1018)
  • Infectious Diseases (except HIV/AIDS) (14632)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4927)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (725)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4215)
  • Public and Global Health (7506)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1014)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)